Catheter Precision Inc. (VTAK), a medical device company, reported on Thursday commercial growth in its LockeT and VIVO product lines through orders via Cardinal Health (CAH) in addition to an expanding U.S. market.
The LockeT is a suture retention device used for wound healing, holding sutures in place during removal of stitches. The device received CE Mark approval in the European Union and is registered with the U.S. Food and Drug Administration (FDA) as a sterile Class 1 product.
The VIVO (View Into Ventricular Onset) system is a non-invasive 3D imaging tool used to visualize the origin of ventricular arrythmias and has received clearance in the EU and FDA.
The company received a purchase order via Cardinal, which services over 90% of hospitals in the U.S., and from the Johns Hopkins Hospital in Baltimore. Additionally, the company signed a placement contract for the VIVO system in Germany.
VTAK is currently trading at $0.19, down 9.11%.
CAH is currently trading down 0.85% at $236.46.
For comments and feedback contact: editorial@rttnews.com
Economic News
What parts of the world are seeing the best (and worst) economic performances lately? Click here to check out our Econ Scorecard and find out! See up-to-the-moment rankings for the best and worst performers in GDP, unemployment rate, inflation and much more.
September 04, 2026 15:08 ET The job report and foreign trade data were the main economic news from the U.S. in the first week of September. Elsewhere in North America, the Canadian central bank announced its latest policy decision. Inflation data from Eurozone was the highlight in Europe. The latest interest rate decision by the Reserve Bank of New Zealand drew attention in Asia.